The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy

10.1038/s41586-024-08276-1

Affiliations
Laura Bornes, Lennart J van Winden, Veerle C M Geurts, Beaunelle de Bruijn, Leyla Azarang, Mirthe Lanfermeijer, Marika Caruso, Natalie Proost, Manon Boeije, Jeroen O Lohuis, Guillaume Belthier, Eulàlia Noguera Delgado, Nadia de Gruil, Judith R Kroep, Marieke van de Ven, Renee Menezes, Jelle Wesseling, Marleen Kok, Sabine Linn, Annegien Broeks, Huub H van Rossum, Colinda L G J Scheele, Jacco van Rheenen

DOI: 10.1038/s41586-024-08276-1

Abstract
The response of breast cancer to neoadjuvant chemotherapy (NAC) varies substantially, even when tumours belong to the same molecular or histological subtype

Keywords
NAC，CD45，tumor

관련 제품

카탈로그 번호	제품명	설명	타겟
HY195127	CD45	Anti-Human CD45/PTPRC Antibody (BC8), PE [BC8] (HY195127) is a mouse monoclonal antibody detecting PTPRC in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.	T200, Leukocyte common antigen, CD45, L-CA, Receptor-type tyrosine-protein phosphatase C, PTPRC

재조합 단백질

항체

어세이 키트

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy

빠른 접근

문의하기